Chinese University of

Company snapshot

Chinese University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor, Essential Hypertension, Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES. NovaPharmaNews links 42 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (16), approved (9), phase 3 (6).

• 42 active pipeline program(s) linked via ClinicalTrials.gov.
• 42 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chinese University of. Not investment advice.

• What is Chinese University of?

  Chinese University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor, Essential Hypertension, Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES. NovaPharm

• Is Chinese University of publicly traded?

  Chinese University of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chinese University of develop or market?

  We link 55 drug profile(s) where Chinese University of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chinese-university-of-hong-kong#company-drugs.

• What are the latest developments for Chinese University of?

  In the last 12 months our linked public records show 42 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Chinese University of focus on?

  Chinese University of focuses on Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor based on our analysis of their pipeline programs and drug development activities.